In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver ...
This article and associated images are based on a poster originally authored by Marina Fedorova and Ian Hiles and presented at ELRIG Drug Discovery 2024 in affiliation with GSK. This poster is being ...
Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins
Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...
This article is based on a poster originally authored by Sunidhi Shetty, Narasimha Murthy Bandaru, Anna Moberg and Marco Manni, which was presented at ELRIG Drug Discovery 2024 in affiliation with ...
Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets To de-risk and shorten path to critical structural and biophysical insights that inform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results